Lactiga is a venture-backed, NIH-funded biotherapeutics company developing patented biologics to treat and prevent mucosal infections with a focus on improving the quality of life in patients with Primary Immunodeficiency Diseases. They are unlocking the full therapeutic value of human milk antibodies to create the next-generation of anti-infectives that can battle even the world’s most dangerous pathogens including Covid. Lactiga has earned multiple awards, media attention (Globe & Mail, CTV, Toronto Star) and is participating in the On Deck Health (ODH2) cohort.
AngelMD Profile: https://www.angelmd.co/en/startups/lactiga
Hall Venture Partners is the venture fund sponsored by and investing alongside the Hall Family. The Halls are a 3rd generation family office that...
AllCore360° exists to empower patients, athletes, seniors, and everyday people to train their core muscles for improved performance and recovery in a new, more...
Beam Wellness was born out of the CEO's experience as a marketer in the cosmetic industry. It's now being incubated at Health Wildcatters in...
